Cardlytics, Inc. (NASDAQ:CDLX – Get Free Report) insider Nicholas Hollmeyer Lynton sold 40,296 shares of the firm’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $0.99, for a total transaction of $39,893.04. Following the sale, the insider directly owned 167,856 shares of the company’s stock, valued at approximately $166,177.44. The trade was a 19.36% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.
Nicholas Hollmeyer Lynton also recently made the following trade(s):
- On Monday, January 5th, Nicholas Hollmeyer Lynton sold 6,253 shares of Cardlytics stock. The stock was sold at an average price of $1.17, for a total value of $7,316.01.
Cardlytics Stock Up 13.0%
CDLX traded up $0.13 during trading on Thursday, hitting $1.13. The company’s stock had a trading volume of 2,137,597 shares, compared to its average volume of 1,043,434. The stock has a market capitalization of $62.23 million, a price-to-earnings ratio of -0.58 and a beta of 0.91. The firm’s 50 day moving average price is $0.90 and its two-hundred day moving average price is $1.34. Cardlytics, Inc. has a 12 month low of $0.66 and a 12 month high of $3.28.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in CDLX. Virtu Financial LLC bought a new position in shares of Cardlytics in the 4th quarter valued at about $39,000. Invesco Ltd. raised its stake in shares of Cardlytics by 38.1% during the fourth quarter. Invesco Ltd. now owns 170,122 shares of the company’s stock worth $196,000 after buying an additional 46,973 shares during the last quarter. Barclays PLC raised its position in Cardlytics by 31,167.6% in the 4th quarter. Barclays PLC now owns 55,969 shares of the company’s stock valued at $64,000 after buying an additional 55,790 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Cardlytics in the fourth quarter valued at about $62,000. Finally, Goldman Sachs Group Inc. grew its position in Cardlytics by 15.1% in the 4th quarter. Goldman Sachs Group Inc. now owns 109,001 shares of the company’s stock worth $125,000 after purchasing an additional 14,273 shares in the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on CDLX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardlytics in a research note on Monday, December 29th. Bank of America restated an “underperform” rating on shares of Cardlytics in a research report on Thursday, March 5th. Finally, Evercore set a $1.00 price objective on Cardlytics in a report on Friday, March 6th. Two analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cardlytics presently has an average rating of “Reduce” and a consensus price target of $1.75.
Read Our Latest Report on Cardlytics
Cardlytics Company Profile
Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.
At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.
Featured Articles
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.
